Calliditas Plans To File For Complete FDA Approval For Rare Kidney Disease Drug After Positive Phase 3 Data

By: via Benzinga
Calliditas Therapeutics AB(NASDAQ: CALT) announcedtopline resultsfrom the Phase 3 clinical trial NefIgArd, which ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.